More generally, prostate cancer is frequently responsive to androgen deprivation therapy, given the high expression and requirement of the androgen receptor (AR) in the development and progression of this disease.40 However, the effectiveness of AR inhibitors in recurrent metastatic disease is highly variable. Here, AR is linked to prostate carcinoma.